Looking at stock performance for the past six months, shares are 23.65%.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Wedge Capital Mgmt L LP Nc holds 0.52% of its portfolio in Boston Scientific Corporation (NYSE:BSX) for 2.48 million shares. Boston Private Wealth LLC now owns 22,890 shares of the medical equipment provider's stock worth $545,000 after buying an additional 85 shares in the last quarter. First Personal Financial Services increased its stake in Boston Scientific by 0.9% in the first quarter. Wade G W & Inc. increased its stake in Boston Scientific by 0.9% in the third quarter. UBS initiated the shares of BSX in report on Tuesday, September 22 with "Buy" rating. They issued a "neutral" rating and a $28.00 target price on the stock. Finally, JNBA Financial Advisors boosted its position in Boston Scientific by 467.9% in the fourth quarter. Hanseatic Management Services Inc. now owns 153,262 shares of the medical equipment provider's stock valued at $3,648,000 after buying an additional 11,147 shares during the last quarter. Guardian Life Insurance Co. of America increased its stake in Boston Scientific by 0.9% in the first quarter.
Boston Scientific Corporation (BSX) belongs to the "Healthcare" sector with an industry focus on "Medical Appliances & Equipment", with Mr. Michael F. Mahoney as Chief Exec. Officer, Pres and Director. About shares traded. Nuveen Select Tax-Free Incom Portfolio 3 (NYSE:NXR) has risen 6.00% since April 19, 2017 and is uptrending.
Since the beginning of the calendar year, the stock is 20.85%. The stock has a market cap of $35.52 billion, a P/E ratio of 83.14 and a beta of 1.06. Boston Scientific has a 12-month low of $19.67 and a 12-month high of $26.76.
NAMI Releases Video Series On College And Mental Health
Treating a mental illness can be hard because a disorder can affect people in different ways, even if they are diagnosed the same. "The next government and employers must do more to support people with mental health conditions".
In terms of Buy, Sell or Hold recommendations, Boston Scientific Corp (NYSE:BSX) has analysts' mean recommendation of 1.8. The medical equipment provider reported $0.29 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.30 by $0.01.
Boston Scientific Corp (NYSE:BSX)'s trailing twelve month revenues are $8.58 Billion, whereas its price to sales ratio for the same period is 4.16. The firm's quarterly revenue was up 10.0% on a year-over-year basis. During the same period in the previous year, the business earned $0.28 earnings per share.
Shares of the company have shown an EPS growth of -15.50% in the last 5 years.
04/27/2017 - Boston Scientific Corporation had its " rating reiterated by analysts at Needham & Company.
Goldman Sachs warns oil prices on the brink of 'capitulation'
Libya and Nigeria are two OPEC members exempt from the production declines so they can lean on oil revenue to help ensure national security.
COPYRIGHT VIOLATION WARNING: "Boston Scientific Co".
TRADEMARK VIOLATION NOTICE: This piece of content was published by Markets Daily and is the property of of Markets Daily. The original version of this news story can be read at https://sportsperspectives.com/2017/05/18/boston-scientific-co-bsx-coverage-initiated-at-goldman-sachs-group-inc.html. A rating of 4 or 5 would represent a Sell recommendation.
To stay one step ahead we extended our research by comparing different price targets. By reviewing stock prices from the stock market history of the company and examining its analysts ratings can give an investment picture with updated information of stock which helps investors to make investing decision. Finally, Stifel Nicolaus boosted their price objective on Boston Scientific from $28.00 to $30.00 and gave the stock a "buy" rating in a report on Friday, April 28th.
Ratings analysis reveals 76% of Boston Scientific Corporation's analysts are positive. $248,725 worth of Boston Scientific Corporation (NYSE:BSX) shares were sold by Pratt Timothy A. The insider Sorenson John Bradley sold $72,747. In that case, its shares would mark a 1.57% decline from the most recent price. Following the sale, the senior vice president now directly owns 34,267 shares in the company, valued at approximately $851,192.28. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The shares were sold at an average price of $24.55, for a total transaction of $1,940,554.75. The disclosure for this sale can be found here. Typically, they estimate what the company's earnings and cash flow will be for the next couple of years, and then apply a ratio - such as a price-to-earnings ratio - to those estimates to determine what the future stock price should theoretically be.
Shedding Light On Growth Forecasts For Amazon.com, Inc. (NASDAQ:AMZN)
Following the completion of the transaction, the director now owns 22,525 shares of the company's stock, valued at $19,146,250. Also, insider David Zapolsky sold 503 shares of the business's stock in a transaction that occurred on Tuesday, February 21st.
About Boston Scientific Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Firm offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.
- Rihanna Glams Up as Chopard's Guest of Honor in Cannes!
- SL Green Realty Corp (SLG) Releases Quarterly Earnings Results, Hits Expectations
- Cabot Oil & Gas Co. (COG) Given "Overweight" Rating at Piper Jaffray Companies
- Sudan president will not attend Saudi summit with Trump
- Wenger pins hopes on last-day Arsenal coup
- French president meeting EU chief, to reveal minister picks
- SYSCO Co. (SYY) Given Consensus Rating of "Hold" by Analysts
- The late Tim Pigott-Smith lauded for performance in King Charles III
- Jimmy Kimmel is coming back as the Oscars host
- Trudeau swats away Super Hornet questions amid Boeing-Bombardier dispute